Clinical Trials Logo

Filter by:
NCT ID: NCT02516774 Withdrawn - Clinical trials for Anaplastic Thyroid Cancers

A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

TAM-RT
Start date: December 2014
Phase: Phase 1
Study type: Interventional

The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and radiotherapy in order to counteract tumor resistance to therapy.

NCT ID: NCT02507258 Withdrawn - Joint Disease Clinical Trials

PMCF Study for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components

Start date: December 2017
Phase:
Study type: Observational

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA and resurfacing devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

NCT ID: NCT02460770 Withdrawn - Clinical trials for Chronic Myocardial Ischemia

Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device

MESAD
Start date: June 2015
Phase: Phase 1
Study type: Interventional

Left Ventricular Assist Devices are commonly used to assist failing hearts as a bridge to transplantation or for long-term support. The purpose of the MESenchymal stem cell therapy and Left Ventricular Assist Device program is to improve heart function with stem cell therapy and attempt to wean patients from HeartMate Left Ventricular Assist Device.

NCT ID: NCT02458040 Withdrawn - Neoplasms Clinical Trials

Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs

Start date: May 2015
Phase:
Study type: Observational

This study is a meta-epidemiological study which aim is to quantify the clinical benefit of the biomarker-based strategy compared to conventional strategy across all drugs with such a strategy.

NCT ID: NCT02405403 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Microglial Activation Role In ALS (MARIA)

MARIA
Start date: March 2015
Phase: Early Phase 1
Study type: Interventional

Neuroinflammation, characterized in particular by microglia activation, is an essential component of Amyotrophic Lateral Sclerosis (ALS) pathogenesis. Translocator Protein (TSPO) is recognized as a specific and sensitive biomarker of neuroinflammation, reflecting disease activity. An experimental radiopharmaceutical specific of TSPO expression, namely [18F]DPA714, allow to quantify this microglial activation using Positon Emission Tomography (PET) imaging. The purpose of this study is to longitudinally correlate the spatial distribution of neuroinflammation with the pro- or anti-inflammatory state of activated microglia cells in ALS, in order to evaluate neurotoxic or neuroprotective microglia activity, by complementary approaches in 20 ALS patients: - in vitro: measuring concentrations of several pro- and anti-inflammatory cytokines secreted by microglial cells in the cerebrospinal fluid (CSF). - in vivo: [18F]DPA714 PET imaging. These assays will be performed in the framework of the clinical follow-up of ALS patients, at the diagnosis of ALS disease and 6 months latter.

NCT ID: NCT02400840 Withdrawn - Cardiac Graft Clinical Trials

Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging

DRAGON
Start date: January 2015
Phase: N/A
Study type: Interventional

Acute heart allograft rejection is a common complication after orthotopic heart transplantation. Primary objective of this study is to assess cardiac MRI as a tool for acute heart graft rejection screening, by detecting changes in myocardium structure especially extracellular volume.

NCT ID: NCT02397395 Withdrawn - Clinical trials for End-stage Renal Disease

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the percentage of participants with sustained virologic response 12 weeks after the actual end of study treatment (SVR12)

NCT ID: NCT02390583 Withdrawn - Internet Addiction Clinical Trials

Internet Addiction and Sleep Disorders

ADDICSOM
Start date: September 2016
Phase: N/A
Study type: Interventional

This is an open label randomized controlled trial, comparing two modes of treatment for internet addiction (gaming or gambling online) with sleep disorders associated.

NCT ID: NCT02368990 Withdrawn - Clinical trials for Non Small Cell Lung Cancer

T790M Mutation Positive 2nd Line STandard of cAre Registry

T-STAR
Start date: June 2015
Phase: N/A
Study type: Observational

The aim of the study is to collect real world information on patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who progressed after first line treatment with an approved Tyrosine-Kinase Inhibitor (TKI), who are known to be T790M positive and have been prescribed second line platinum-based chemotherapy (Pemetrexed + Cisplatin /Carboplatin).

NCT ID: NCT02356367 Withdrawn - Heart Failure Clinical Trials

French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS, AirCurve 10CS): Predictive Factors of Poor Compliance (FACE)

FACE
Start date: May 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine the predictive factors of poor compliance to sleep disordered breathing therapy in chronic heart failure patients treated for central sleep apnea. To characterize nocturia pathophysiology associated with SDB in this population. To use telemonitoring data to define predictive factors of poor compliance.